Multiomics provides a comprehensive view of biological systems at multiple layers. The global multiomics market witnesses increasing demand owing to the rising integration of multiomics data in precision medicine and clinical research. Multiomics studies molecular alterations and interactions within biological systems simultaneously across different levels such as DNA, RNA, proteins, and metabolites. This helps scientists gain deeper biological insights and develop effective disease diagnosis, prognosis, treatment selection, and management. Growing healthcare expenditure globally is prompting the adoption of advanced medical technologies like multiomics for improving patient outcomes.

The Global Multiomics Market is estimated to be valued at US$ 2.46 Bn in 2024 and is expected to exhibit a CAGR of 15% over the forecast period 2024 To 2031.

Rising adoption of multiomics approach in drug discovery and precision medicine is a key growth driver. Multiomics assists healthcare providers in delivering personalized care by understanding disease heterogeneity at the molecular level.

Key Takeaways

Key players operating in the Global Multiomics market are BD, Thermo Fisher Scientific Inc., Illumina, Inc, Danaher, PerkinElmer Inc., Shimadzu Corporation, Bruker, QIAGEN, Agilent Technologies, Inc., and BGI. These players are focusing on new product launches and partnerships to strengthen their market position. For instance, in June 2022, Agilent Technologies launched a new microfluidic chip to expand its Fluidigm multiomics solutions.

The key opportunities in the Global Multiomics Market Size include increasing investments in multiomics-based clinical research by biopharma companies and growing availability of big multiomics data. Multiomics is enabling drug developers to identify biomarkers and patient subtypes for developing more targeted therapies.

North America holds the largest share in the global multiomics market due to availability of research funding and advanced healthcare infrastructure. However, Asia Pacific is anticipated to offer lucrative growth opportunities owing to rising healthcare spending, improving research capabilities, and growing focus on precision medicine in countries like China and India. Key players are expanding their presence in Asian markets through collaborations.

Market Drivers
The rising adoption of precision medicine approach for diagnosis and treatment selection is a major driver for the global multiomics market. Precion medicine relies on understanding molecular changes and heterogeneity at multi-omics levels to develop targeted therapies. According to National Institutes of Health, the global spending on precision medicine is estimated to reach US$ 75 Bn by 2025.

Market Restrain
High capital requirement for installation of multiomics technologies and lack of skilled professionals for data analysis can restrain the market growth. Integration of large multiomics datasets also poses challenges. Standardization of tools and workflows is needed for multiomics to reach its full potential.
Segment Analysis
The global multiomics market is dominated by integrated omics sub segment which accounts for nearly 30% of the overall market share. Integrated omics involves the analysis and interpretation of multiple types of omics data, such as genomics, transcriptomics, proteomics and metabolomics simultaneously. It provides a deeper understanding of biological systems at molecular level. Growing application of integrated omics approach in precision medicine, development of novel therapies and diagnostics is driving the growth of this sub segment.

Transcriptomics sub segment held the second largest share and is expected to witness significant growth during the forecast period. Rising application of transcriptome analysis in preclinical drug development and disease diagnosis is propelling the growth of transcriptomics sub segment. Additionally, ongoing advancement in RNA sequencing technologies is further supporting the growth of this sub segment.

Regional Analysis
North America dominated the global multiomics market and accounted for more than 40% revenue share in 2024 owing to presence of well-established healthcare infrastructure, technological advancements and adoption of omics technologies. Asia Pacific exhibits the fastest growth over the forecast period attributed to improving R&D investments, expansion of global market players into emerging economies and growing awareness regarding personalized medicine and precision diagnosis. In addition, rising healthcare expenditure and increasing government initiatives to promote adoption of advanced omics technologies further support the regional market growth.
Get more insights on This Topic- Global Multiomics Market